Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 9/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 3/20 | 0.49 |
| ▸ | PPARD | Q03181 | 3/20 | 0.49 |
| ▸ | PPARA | Q07869 | 3/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PKLR | P30613 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20046992 | 0.87 | HDAC6 (0.69) | AKR1C3HDAC6HDAC1ESR2PPARG | |
| SCHEMBL20046995 | 0.81 | CYP11B1 (0.47) | AKR1C3HDAC6HDAC1HTTESR2 | |
| SCHEMBL20047145 | 0.81 | HDAC6 (0.49) | AKR1C3HDAC6HDAC1HTTESR2 | |
| SCHEMBL31670441 | 0.77 | AKR1C3 (0.73) | AKR1C3ESR2PPARGPPARDPPARA | |
| SCHEMBL3058949 | 0.76 | AKR1C3 (0.60) | AKR1C3HTTPKMKMT2A | |
| SCHEMBL1677156 | 0.76 | HTT (0.65) | HTTPKMPKLRMEN1KMT2A | |
| SCHEMBL20046985 | 0.75 | AKR1C3 (0.60) | AKR1C3HDAC6HTTESR2AKR1C1 | |
| SCHEMBL2590065 | 0.75 | AKR1C3 (0.60) | AKR1C3HDAC6ESR2PKMMEN1 | |
| SCHEMBL8211817 | 0.75 | HTT (0.64) | HTTPKMPKLRMEN1KMT2A | |
| SCHEMBL3057061 | 0.75 | AKR1C3 (0.56) | AKR1C3HTTPKMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746097-B2 | LXR inverse agonists for treatment of cancer | SAINT LOUIS UNIVERSITY (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746097-B2 | LXR inverse agonists for treatment of cancer | SAINT LOUIS UNIVERSITY (US) | 2023-09-05 | — | — | US | disclosed |
| US-20200308135-A1 | LXR INVERSE AGONISTS FOR TREATMENT OF CANCER | SAINT LOUIS UNIVERSITY (US) | 2020-10-01 | — | — | US | disclosed |
| WO-2017223514-A9 | LXR INVERSE AGONISTS FOR TREATMENT OF CANCER | SAINT LOUIS UNIVERSITY (US) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308135-A1 | LXR INVERSE AGONISTS FOR TREATMENT OF CANCER | NR1H2, NR1H3, PPARD | AKR1C3 1019/4885HDAC6 2050/4885HDAC1 825/4885 |
| US-11746097-B2 | LXR inverse agonists for treatment of cancer | NR1H2, NR1H3, PPARD | AKR1C3 1019/4885HDAC6 2050/4885HDAC1 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.